ReviewNature reviews. Urology2025
Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.
Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes.Frontiers in immunology · 2026Trial
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.Future science OA · 2026Review
- Overcoming barriers to bladder preservation: Emerging intravesical therapies for high-risk non-muscle-invasive bladder cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- [CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of FourCancers · 2026Article
- Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.The Journal of biological chemistry · 2026Article
- Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.Molecular biomedicine · 2026Article
- Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.Nature communications · 2026Article
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.BMC cancer · 2026Article
- A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer.Scientific reports · 2026Article
- Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway.Cancers · 2026Article
- An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.Functional & integrative genomics · 2026Article
- Intratumoral and Peritumoral Fat CT‑Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.Annals of surgical oncology · 2026Article
- Stromal FAPClinical and translational medicine · 2026Article
- A molecular landscape tracking the progression of non-muscle invasive bladder cancer.World journal of urology · 2026Review
- Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.Translational oncology · 2026Article
- Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.Clinical and translational medicine · 2026Article
- Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global incidence of bladder cancer is more than half a million diagnoses each year. Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC), which accounts for ~75% of diagnoses, and muscle-invasive bladder cancer (MIBC). Up to 45% of patients with NMIBC develop disease progression to MIBC, which is associated with a poor outcome, highlighting a clinical need to identify these patients. Current risk stratification has a prognostic value, but relies solely on clinicopathological parameters that might not fully capture the complexity of disease progression. Molecular research has led to identification of multiple crucial players involved in NMIBC progression. Identified biomarkers of progression are related to cell cycle, MAPK pathways, apoptosis, tumour microenvironment, chromatin stability and DNA-damage response. However, none of these biomarkers has been prospectively validated. Reported gene signatures of progression do not improve NMIBC risk stratification. Molecular subtypes of NMIBC have improved our understanding of NMIBC progression, but these subtypes are currently unsuitable for clinical implementation owing to a lack of prospective validation, limited predictive value as a result of intratumour subtype heterogeneity, technical challenges, costs and turnaround time. Future steps include the development of consensus molecular NMIBC subtypes that might improve conventional clinicopathological risk stratification. Prospective implementation studies of biomarkers and the design of biomarker-guided clinical trials are required for the integration of molecular biomarkers into clinical practice.
Indexed as
Identifiers
39095581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.